The purpose of this study is to evaluate how safe and tolerable the combination of MK-2870 and chemotherapy is for patients. The study will also look at how well the treatment works in shrinking or controlling the cancer. Participants will receive the study medications through an intravenous infusion, which means the drugs are given directly into a vein. The study will monitor participants for any side effects and measure how the cancer responds to the treatment over time.

In addition to MK-2870 and paclitaxel, the study may involve other medications such as buclizine hydrochloride, paracetamol (also known as acetaminophen), codeine phosphate, ramucirumab, and glucocorticoids. These medications may be used to manage symptoms or side effects. The study aims to provide valuable information on the potential benefits and risks of these combination therapies for patients with advanced gastroesophageal cancer.

Patients in this study will receive zanidatamab on its own, without combining it with other cancer treatments. The medicine will be given regularly over a treatment period that can last up to 60 weeks. The doctors will check how the tumors respond to the treatment by doing regular scans and tests. Some patients in the study may have breast cancer or cancers of the stomach and food pipe area, and they may have received a specific type of HER2-targeted therapy before, which is a treatment that works against the HER2 protein. For other types of solid tumors, patients should not have had this type of treatment before.

During the study, doctors will monitor patients carefully to see if the treatment is working and to watch for any side effects. This includes checking heart function, blood tests to see how the liver and kidneys are working, and measuring the size of the tumors. Patients will also be asked about symptoms they experience using questionnaires. The study will look at how many patients see their tumors shrink, how long the treatment keeps working, and how long patients live. Blood samples will be taken to measure the amount of medicine in the body and to check if the body makes any reaction against the medicine.

The purpose of this study is to find out whether tislelizumab given as an injection under the skin reaches the same levels in the body as when it is given through a vein, and to see if the injection under the skin is as safe and effective as the intravenous method. The study will measure the amount of medication in the blood at different times and compare the results between the two groups. Researchers will also look at how well the treatment works by checking whether tumors shrink or stop growing, how long patients live without their cancer getting worse, and how long the treatment keeps working.

During the study, patients will receive tislelizumab in one of the two ways mentioned, along with chemotherapy, as their first treatment for this type of advanced cancer. The treatment can continue for up to 24 months. Throughout the study, doctors will monitor patients for any side effects and collect information about how the cancer responds to treatment. Patients will need to provide tumor tissue samples for testing, and the study will also check whether the body develops any immune responses against the medication.

The main purpose of this study is to find out if adding FRUZAQLA to Lonsurf helps people live longer compared to taking Lonsurf alone. The study will also look at how long patients live without their cancer getting worse, how well the tumors respond to treatment, and how the treatments affect quality of life. The safety of the treatments will be carefully monitored, and any side effects will be recorded. Patients will be assigned randomly to one of the two treatment groups, meaning that neither the patient nor the doctor chooses which treatment is given.

During the study, patients will take their assigned medicines for up to six months, and their health will be regularly checked through medical examinations and scans to see how the cancer is responding. Quality of life will be measured using questionnaires that ask about daily activities and symptoms. The study is expected to start enrolling patients in early 2026 and continue until early 2029. Patients will need to provide tumor tissue samples for testing and agree to participate in additional biological studies as part of the research.

The purpose of the study is to see how well this combination works in preventing the cancer from getting worse over a year. Participants will receive these treatments through an intravenous infusion, which means the medication is given directly into a vein. The study will also include other medications like Fluorouracil, known as 5-FU, and Calcium Levofolinate, which help enhance the effects of chemotherapy. Additionally, some participants may receive Simvastatin in tablet form to see if it improves treatment outcomes.

Throughout the study, participants will be monitored to assess how the cancer responds to the treatment and to check for any side effects. The study will last up to 60 weeks, during which the health and quality of life of the participants will be regularly evaluated. The goal is to determine if this treatment approach can help patients live longer without the cancer progressing. The trial will also compare results with a group of patients who do not have the ARID1A mutation to see if there are differences in treatment effectiveness.

The purpose of the study is to evaluate the safety and effectiveness of these combination therapies when given before surgery to patients with this type of cancer. The study will involve several phases, where participants will receive the treatment and be monitored for any side effects or changes in their condition. The goal is to determine if this combination of treatments can be safely administered and if it helps in reducing the cancer before surgery.

Participants in the study will receive either the combination of trastuzumab deruxtecan and other medications or a placebo. The study will track how well patients tolerate the treatment and any side effects they experience. The results will help researchers understand if this treatment approach is a viable option for patients with HER2-positive esophagogastric adenocarcinoma.

Participants in the study will receive sertraline in addition to their standard immunochemotherapy treatment. The study will observe how well the cancer responds to this combination over a period of time. The medication sertraline is taken orally, meaning it is swallowed in the form of a tablet. The study will last for a specific period, during which the effects of the treatment will be closely monitored.

The main goal of the study is to evaluate how well the cancer responds to the treatment combination. Researchers will also look at other important factors such as how long patients live without the cancer getting worse, overall survival, any side effects experienced, and the quality of life of the participants. Additionally, the study will assess the impact of the treatment on depression, as sertraline is commonly used to treat this condition. The findings from this study could provide valuable insights into improving treatment options for patients with advanced gastroesophageal cancer.

Participants in the study will receive Trifluridine/tipiracil as part of their first-line treatment for their cancer. The study will monitor the safety of this treatment over a period of time, specifically looking for any severe side effects. The trial will also assess how well the treatment controls the cancer, including measuring the disease control rate after two months of treatment. Other medications involved in the study include Nivolumab, Panitumumab, Bevacizumab, Trastuzumab, and Oxaliplatin, which may be used in combination with Trifluridine/tipiracil depending on the specific needs of the patient.

The study will last for several years, with regular assessments to check the health-related quality of life of the participants. This will be done using specific questionnaires designed for patients with colorectal or gastroesophageal cancer. The goal is to ensure that the treatment not only controls the cancer effectively but also maintains a good quality of life for the patients involved in the trial.

Participants in the study will receive the treatment through an intravenous infusion, which means the medication is given directly into a vein. The study will also include other medications such as Leucovorin, Taxotere (docetaxel), medoxa (oxaliplatin), and 5-FU (fluorouracil), which are commonly used in chemotherapy. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of the treatment. The purpose of the study is to assess how effective this treatment is in avoiding surgery and reducing the risk of complications, as well as to monitor the response of the cancer to the treatment.

The study will take place over several months, with regular check-ups and evaluations to monitor the participants’ health and the progress of the treatment. The main focus will be on the rate of complete response, meaning the cancer is no longer detectable, at the time of endoscopic re-evaluation, which is a procedure that uses a camera to look inside the esophagus. The study will also look at the long-term effects of the treatment, including the rate of response after one, two, and three years, as well as any side effects or adverse events that may occur. Participants will be closely monitored to ensure their safety and well-being throughout the study.

The purpose of the study is to see if adding atezolizumab to the FLOT regimen can improve outcomes for patients. Participants in the study will receive treatment over a period of up to 12 months. The study will monitor how well the cancer responds to the treatment and how long patients remain free from cancer progression or relapse after surgery. Some participants will receive the combination of atezolizumab and FLOT, while others will receive only the FLOT regimen. A placebo may be used in some cases to help compare the effects of the treatments.

Throughout the study, participants will undergo regular assessments to monitor their health and the status of their cancer. These assessments may include imaging tests like MRI or CT scans to check for changes in the cancer. The study aims to provide valuable information on whether the addition of atezolizumab can offer better outcomes for patients with these types of cancer. The trial is expected to continue until 2028, with the goal of improving treatment options for patients with gastric cancer and adenocarcinoma of the esophagogastric junction.

The purpose of the study is to evaluate the safety and effectiveness of these combination therapies in treating gastroesophageal cancer. Participants will receive these treatments through different methods, such as oral use or intravenous infusion, which means the medication is given directly into a vein. The study will begin with a phase to ensure the safety and tolerability of the treatments, followed by an assessment of how well the treatments work in reducing the size of the cancer or stopping its growth.

Throughout the study, participants will be closely monitored for any side effects or adverse reactions to the treatments. The study aims to provide valuable information on the potential benefits and risks of these combination therapies for individuals with advanced gastroesophageal cancer. The trial is expected to continue until 2029, with recruitment starting in 2024.

The purpose of the study is to evaluate how well Bemarituzumab works in combination with these other treatments for patients who have already tried at least one other chemotherapy treatment without success. The study will involve different groups of patients receiving different combinations of these medications. Some patients may receive a combination of Bemarituzumab and Irinotecan, others may receive Bemarituzumab with Paclitaxel and Ramucirumab, and another group may receive Bemarituzumab with Trifluridine/Tipiracil. There is also a possibility of receiving a placebo, which is a substance with no active medication.

Participants in the study will receive their assigned treatment over a period of up to 12 months. The treatments will be given either as tablets taken by mouth or as infusions, which are medications delivered directly into the bloodstream through a vein. The study aims to determine the effectiveness of these treatment combinations in shrinking the cancer or stopping it from growing. The results will help doctors understand if these combinations can be a better option for treating this type of cancer in the future.

Nivolumab, also known by its code name BMS-936558, is given as an infusion, which means it is administered directly into the bloodstream through a vein. The study will observe patients over a period to see if the cancer returns or if they remain disease-free. The main goal is to see how long patients can live without the cancer coming back, which is referred to as disease-free survival. Additionally, the study will look at overall survival, which is the length of time patients live after starting the study, regardless of whether the cancer returns.

Participants in the study will receive either nivolumab or a placebo, and neither the patients nor the researchers will know which treatment each patient is receiving. This is known as a double-blind study, which helps ensure that the results are not influenced by expectations about the treatment. The study aims to provide valuable information on whether nivolumab can help prevent the return of esophageal or gastroesophageal junction cancer after surgery.

The purpose of this study is to explore how these treatments affect the immune system’s response to the cancer. Specifically, the study will look at changes in a protein called Interferon gamma (IFN-γ) and the presence of certain immune cells known as cytotoxic T cells in the tumor environment. These immune cells are important because they can help the body fight cancer. The study will involve several stages, starting with initial treatment using Capecitabine and Oxaliplatin, followed by maintenance treatment with Retifanlimab. The study will also include a comparison with a placebo to better understand the effects of the treatment.

Participants in the study will receive the treatment over a period of time, with regular assessments to monitor their response. The study aims to gather information on overall survival, progression-free survival, and the response rate to the treatment. Additionally, it will track any side effects experienced by participants and assess their quality of life during the study. The ultimate goal is to determine if this combination of treatments can provide a beneficial effect for patients with this type of cancer.

The purpose of the study is to determine if the combination of trifluridine/tipiracil and oxaliplatin, with or without nivolumab, is better at delaying the progression of cancer compared to a regimen called FOLFOX, which includes fluorouracil, oxaliplatin, and folinic acid, with or without nivolumab. The study will follow patients over a period to monitor how their cancer responds to the treatment and to assess their overall health and quality of life. Patients will receive their assigned treatment and will be regularly monitored by healthcare professionals to track the progress of their disease and any side effects they may experience.

This trial aims to provide valuable information on the effectiveness and safety of these treatment combinations for patients with advanced gastric, esophageal, or gastroesophageal junction cancer. The results could help improve treatment options for these patients in the future.

The purpose of this study is to determine how well the combination of regorafenib and nivolumab, referred to as RegoNivo, improves the overall survival of patients compared to standard chemotherapy treatments. Participants in the study will be randomly assigned to receive either the RegoNivo treatment or the standard chemotherapy. The study will last for a period of up to 24 months, during which participants will receive regular treatments and follow-up assessments to monitor their health and the progression of the cancer.

Throughout the study, researchers will collect information on various aspects, such as how long patients live, how the cancer responds to the treatment, and the quality of life of the participants. The study will also look at the safety of the treatment by monitoring any side effects that may occur. This research aims to provide valuable insights into the potential benefits of using RegoNivo for treating advanced gastro-oesophageal cancer.

Participants in the study will receive an injection of the tracer [68Ga]Ga-FAPI-46, which will help doctors see the cancer more clearly during the PET/CT scan. The study will compare these images to those obtained from standard imaging methods like CT or MRI. Another substance, iodixanol, which is a type of contrast used in imaging, may also be used to help improve the clarity of the images. The goal is to determine if the new imaging method can detect cancer more accurately and help in planning the best treatment approach.

The study will take place over a period of time, with participants undergoing the imaging process and then being monitored to see how the new imaging method affects their treatment plan. The researchers hope that this new approach will lead to better outcomes for patients by providing more detailed information about the cancer, which can help in making more informed decisions about surgery and other treatments.

The purpose of the study is to compare how well these two imaging methods work in detecting cancer at different stages, both before and after chemotherapy treatment. Participants will undergo scans using both 68Ga-FAPI-46 and Fluor-18-FDG to see which method provides more accurate information about the cancer’s location and size. This will help doctors determine the best way to stage the cancer, which means understanding how far it has spread, and to plan the most effective treatment.

Throughout the study, researchers will also explore how feasible it is to use 68Ga-FAPI-46 in routine practice and identify any potential limitations of this new imaging method. The study will involve several visits for scans and assessments, but it does not require any surgical procedures. The information gathered from this trial could lead to improved imaging techniques for patients with gastric and gastroesophageal junction cancer, potentially leading to better treatment outcomes.

The purpose of the study is to see if the new treatment combination can help clear a specific type of cancer-related DNA, known as ctDNA, from the blood. This DNA is a marker that can indicate the presence of cancer cells. The study will involve patients who have already undergone surgery and chemotherapy but still have minimal residual disease, which means small amounts of cancer cells remain in the body. The trial will last for about a year, during which patients will receive either the new treatment combination or continue with the standard chemotherapy regimen.

Throughout the study, researchers will monitor the patients’ health and track the presence of ctDNA in their blood. They will also assess other outcomes, such as how long patients remain free from cancer recurrence and overall survival rates. The goal is to determine if the new treatment is more effective than the standard options in reducing the risk of cancer returning and improving patient outcomes.

The purpose of the study is to evaluate how well the [68Ga]Ga-FAPI-46 tracer works in detecting cancerous lesions, which are areas of abnormal tissue that may indicate cancer. Participants in the study will receive an injection of the tracer, and then undergo a PET/CT scan, which combines two types of imaging: positron emission tomography (PET) and computed tomography (CT). This scan will be done shortly after the injection to see how sensitive the tracer is in identifying cancerous areas compared to the usual imaging methods.

The study will help determine if using [68Ga]Ga-FAPI-46 can improve the accuracy of cancer diagnosis and assist in planning surgeries or other treatments. By comparing the new imaging method with current practices, researchers aim to find out if it can lead to better management of these cancers. The study will also look at how the tracer is taken up by cancerous lesions, which could provide additional insights into its effectiveness.

The purpose of this study is to understand how safe and tolerable these treatment combinations are for patients with advanced stages of gastric cancer that cannot be removed by surgery. The study will also look at whether adding DKN-01 to the treatment improves the time patients live without the cancer getting worse, which is known as progression-free survival. The study is divided into different parts, with some patients receiving the new treatment combinations as their first treatment and others receiving it after previous treatments have not worked.

Participants in the study will receive the treatments through an intravenous method, which means the medication is given directly into a vein. The study will last for a period of up to 24 months, during which time the safety and effects of the treatments will be closely monitored. The study aims to provide valuable information on the potential benefits of these new treatment combinations for patients with advanced gastric cancer.

The purpose of the study is to assess how well these treatments work together in preventing the cancer from returning and achieving a complete response, meaning no signs of cancer remain after treatment. Participants in the study will receive these treatments before and after surgery to remove the cancer. The study will monitor the participants’ health and response to the treatment over a period of time, with regular check-ups and assessments to ensure safety and effectiveness.

Throughout the study, participants will receive the treatments through intravenous infusions, which means the medication is delivered directly into the bloodstream through a vein. The study aims to provide valuable information on the potential benefits of combining these treatments for patients with HER2-positive esophagogastric adenocarcinoma, contributing to the development of more effective cancer therapies.

The purpose of the study is to compare how long patients can live without their cancer getting worse, known as progression-free survival, and to assess the side effects, particularly nerve damage, of the treatments. Patients will receive one of the treatment combinations, which may include a placebo, and their health will be monitored over time. The study will also look at the overall survival of patients, their quality of life, and how they respond to the treatments according to specific medical guidelines.

Participants in the study will receive treatment through different methods, such as oral tablets or intravenous infusions, which means the medication is given directly into a vein. The study will last for several months, and patients will have regular check-ups to monitor their progress and any side effects. The goal is to find the most effective treatment plan for patients with esophagogastric cancer, improving their chances of living longer and with a better quality of life.